Genetic assessment of efficacy and safety profiles of coagulation cascade proteins identifies Factors II and XI as actionable anticoagulant targets.

Éloi Gagnon Arnaud Girard Jérôme BourgaultErik AbnerDipender GillSébastien ThériaultMarie-Claude Vohl Andre TchernofTõnu EskoPatrick Mathieu Benoit J Arsenault

Published in: European heart journal open (2024)

These results provide strong genetic evidence that F2 and F11 may represent safe and efficacious therapeutic targets to prevent VTE and cardioembolic strokes without substantially increasing bleeding risk.

Keyphrases

genome wide
venous thromboembolism
atrial fibrillation
copy number
dna methylation